Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease

被引:23
|
作者
Mango, Robert L. [1 ]
Matteson, Eric L. [1 ,2 ]
Crowson, Cynthia S. [1 ,2 ]
Ryu, Jay H. [3 ]
Makol, Ashima [1 ,4 ]
机构
[1] Mayo Clin Coll Med & Sci, Div Rheumatol, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med & Sci, Dept Hlth Sci Res, Rochester, MN USA
[3] Mayo Clin Coll Med & Sci, Div Pulm & Crit Care Med, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Rheumatol, 200 1st St SW, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Systemic sclerosis; Interstitial lung disease; Non-specific interstitial pneumonia; Usual interstitial pneumonia; Mortality modeling; IDIOPATHIC PULMONARY-FIBROSIS; SCLERODERMA LUNG; RISK PREDICTION; STAGING SYSTEM; SURVIVAL; TRIALS; SMOKING; PLACEBO; TRENDS; COHORT;
D O I
10.1007/s00408-018-0126-6
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis. The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded. The performance of the models was assessed using standardized mortality ratios (SMR) of observed versus predicted outcomes for calibration and concordance (c)-statistics for discrimination. SSc-ILD patients with usual interstitial pneumonia (31, 17%) had a higher mortality than those with non-specific interstitial pneumonia (147, 83%) (hazard ratio 2.27; 95%CI 1.03-4.97). All 3 models had comparable discrimination (c = 0.72, 0.72, and 0.71, respectively). Regarding calibration, the ILD-GAP model underestimated mortality (SMR 1.50; 95%CI 1.05-2.14). Calibration was acceptable for SADL (SMR 1.00; 95%CI 0.70-1.44) and GAP (SMR 0.90; 95%CI 0.63-1.29). The SADL model underestimated mortality in Stage I ILD. The ILD-GAP model underestimated mortality, and the SADL model underestimated mortality in certain subgroups. However, the GAP model performed well in this cohort, providing the best prognostic information for SSc-ILD.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [31] Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Sim, Myung
    Li, Ning
    Khanna, Dinesh
    Roth, Michael D.
    Clements, Philip J.
    Hoffmann-Vold, Anna-Maria
    Furst, Daniel E.
    Kim, Grace
    Goldin, Jonathan
    Elashoff, Robert M.
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (10) : 1316 - 1325
  • [32] Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
    Volkmann, Elizabeth
    Furst, Daniel E.
    Saggar, Rajeev
    Clements, Philip J.
    Torres, Bryant
    Yoder, Lynne
    Saggar, Rajan
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1179 - S1180
  • [33] Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial
    Nupoor Acharya
    Shefali Khanna Sharma
    Debashish Mishra
    Sahajal Dhooria
    Varun Dhir
    Sanjay Jain
    Rheumatology International, 2020, 40 : 703 - 710
  • [34] Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease
    Moore, O. A.
    Proudman, S. M.
    Goh, N.
    Corte, T. J.
    Rouse, H.
    Hennessy, O.
    Morrisroe, K.
    Thakkar, V.
    Sahhar, J.
    Roddy, J.
    Youssef, P.
    Gabbay, E.
    Nash, P.
    Zochling, J.
    Stevens, W.
    Nikpour, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (04) : S111 - S116
  • [35] Nailfold Videocapillaroscopy Changes Are Associated With the Presence and Severity of Systemic Sclerosis-Related Interstitial Lung Disease
    Caetano, Joana
    Paula, Filipe S.
    Amaral, Marta
    Oliveira, Susana
    Alves, Jose D.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 (03) : E12 - E15
  • [36] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Gkiouras, Konstantinos
    Grammatikopoulou, Maria G.
    Simopoulou, Theodora
    Daniil, Zoe
    Bogdanos, Dimitrios P.
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3379 - 3380
  • [37] Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease
    Konstantinos Gkiouras
    Maria G. Grammatikopoulou
    Theodora Simopoulou
    Zoe Daniil
    Dimitrios P. Bogdanos
    Clinical Rheumatology, 2021, 40 : 3379 - 3380
  • [38] Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease
    Launay, David
    Humbert, Marc
    Berezne, Alice
    Cottin, Vincent
    Allanore, Yannick
    Couderc, Louis-Jean
    Bletry, Olivier
    Yaici, Azzedine
    Hatron, Pierre-Yves
    Mouthon, Luc
    Le Pavec, Jerome
    Clerson, Pierre
    Hachulla, Eric
    CHEST, 2011, 140 (04) : 1016 - 1024
  • [39] Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
    Schniering, Janine
    Benesova, Martina
    Brunner, Matthias
    Feghali-Bostwick, Carol A.
    Schibli, Roger
    Distler, Oliver
    Mueller, Cristina
    Maurer, Britta
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [40] Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis-related interstitial lung disease
    Morrisroe, Kathleen
    Hansen, Dylan
    Stevens, Wendy
    Ross, Laura
    Sahhar, Joanne
    Ngian, Gene-Siew
    Hill, Catherine L.
    Host, Lauren
    Walker, Jennifer
    Proudman, Susanna
    Nikpour, Mandana
    RHEUMATOLOGY, 2023, 63 (07) : 1874 - 1881